Legend Biotech Corporation (LEGN)
NASDAQ: LEGN · Real-Time Price · USD
23.56
-0.09 (-0.38%)
At close: Apr 28, 2026, 4:00 PM EDT
23.40
-0.16 (-0.68%)
After-hours: Apr 28, 2026, 5:50 PM EDT
Legend Biotech Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for Legend Biotech stock have an average target of 61.33, with a low estimate of 21 and a high estimate of 80. The average target predicts an increase of 160.31% from the current stock price of 23.56.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Legend Biotech stock from 12 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 8 | 8 | 8 | 8 | 8 | 7 |
| Hold | 1 | 1 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 14 | 14 | 14 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +112.22% | Apr 21, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +112.22% | Apr 15, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $50 → $49 | Buy | Maintains | $50 → $49 | +107.98% | Mar 11, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $66 → $62 | Buy | Maintains | $66 → $62 | +163.16% | Mar 11, 2026 |
| Barclays | Barclays | Buy Maintains $90 → $80 | Buy | Maintains | $90 → $80 | +239.56% | Feb 4, 2026 |
Financial Forecast
Revenue This Year
1.47B
from 1.03B
Increased by 42.68%
Revenue Next Year
1.92B
from 1.47B
Increased by 30.52%
EPS This Year
0.20
from -1.62
EPS Next Year
1.13
from 0.20
Increased by 466.53%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 1.6B | 2.2B | ||||||
| Avg | 1.5B | 1.9B | ||||||
| Low | 1.3B | 1.5B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 58.4% | 51.6% | ||||||
| Avg | 42.7% | 30.5% | ||||||
| Low | 24.5% | 2.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 0.65 | 1.92 | |
| Avg | 0.20 | 1.13 | |
| Low | -0.20 | 0.56 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | 865.5% | |
| Avg | - | 466.5% | |
| Low | - | 180.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.